Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...

Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its ...

Adults on dupilumab for severe chronic rhinosinusitis with nasal polyps had better outcomes than those who used omalizumab, ...

Key findings of subgroup analyses included an observed increased psoriasis risk in patients without atopic comorbidities (HR 1.42, 95% CI 1.06-1.89) and those with pretreatment immunoglobulin E (IgE) ...

USA: A recent case report published in The Open Dermatology Journal has brought attention to the successful use of ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

DC-15442 inhibits the same IL-4/IL-13 signaling pathway as dupilumab by blocking the interaction between unphosphorylated STAT6 (uSTAT6) and the IL-4Ra receptor, and by preventing nuclear ...

Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use co ...

Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps ... (IL-13) pathways and is not an immunosuppressant.